April 22nd 2024
The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
An Overview of ABT-199 for the Treatment of CLL
February 12th 2014Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the Bcl-2 inhibitor ABT-199 for the treatment of patients with CLL.
Watch
A Phase II Trial Investigating Vemurafenib for the Treatment of Hairy Cell Leukemia
January 24th 2014Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Cancer Center, describes the design of a trial analyzing vemurafenib for the treatment of patients with hairy cell leukemia.
Watch
Efficacy and Safety of Idelalisib and Rituximab for Previously Treated CLL
January 8th 2014Richard R. Furman, MD, Richard A. Stratton Assistant Professor in Hematology and Oncology, Weill Cornell Medical College, gives an overview of the efficacy and safety of idelalisib and rituximab for previously treated CLL.
Watch
A Preview of the 2013 ASH Annual Meeting
December 5th 2013Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Alan N. Houghton Chair, Memorial Sloan-Kettering Cancer Center, highlights two studies that will be presented at the 2013 American Society of Hematology (ASH) Meeting.
Read More
Frontline Obinutuzumab (Gazyva) Approved for CLL
November 1st 2013Obinutuzumab (Gazyva) plus chlorambucil has been approved by the FDA as a first-line treatment for patients with CLL, based on clinical trial data demonstrating that the combination more than doubled median PFS over the chemotherapy agent alone.
Read More
Ponatinib Trial Discontinued Following Occurrence of Arterial Thrombotic Events
October 21st 2013A phase III EPIC trial exploring ponatinib (Iclusig) in untreated patients with chronic myeloid leukemia (CML) has been discontinued. The decision comes following a high occurrence of arterial thrombotic events, according to a statement released by Ariad Pharmaceuticals, Inc., the company developing the drug.
Read More